Neurocrine Announces Negative Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia; Company To Host Conference Call And Webcast Monday, September 9th At 5:00PM ET
Eddie Staley